ABEO
NASDAQAbeona Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$5.39-0.16 (-2.88%)
01:30 PM07:45 PM
News · 26 weeks58-50%
2025-12-142026-06-07
Mix2990d
- SEC Filings10(34%)
- Insider8(28%)
- Other7(24%)
- Earnings3(10%)
- Leadership1(3%)
Latest news
25 items- SECAbeona Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- PRAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On May 31, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,800 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the s
- INSIDERDirector Alvino Mark gifted 500 shares, decreasing direct ownership by 0.64% to 77,065 units (SEC Form 4)4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- PRAbeona Therapeutics® Announces Participation in Upcoming Investor ConferencesCLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026: 2026 Jefferies Global Healthcare Conference: Fireside chat at 3:10 PM ET on Thursday, June 4, 2026 and investor meetings.Goldman Sachs 47th Annual Global Healthcare Conference 2026: Investor meetings on Monday, June 8, 2026. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events, where a replay of the event will also be available for a limited time. About Abeona Therapeutics Abeona
- INSIDERDirector Alvino Mark sold $35,463 worth of shares (6,500 units at $5.46), decreasing direct ownership by 8% to 77,565 units (SEC Form 4)4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERDirector Crombez Eric sold $144,636 worth of shares (26,143 units at $5.53) as part of a pre-agreed trading plan, decreasing direct ownership by 41% to 37,313 units (SEC Form 4)4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- SECSEC Form 10-Q filed by Abeona Therapeutics Inc.10-Q - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- SECAbeona Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- PRAbeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update- Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first
- INSIDERChief Commercial Officer Vasanthavada Madhav sold $33,073 worth of shares (5,548 units at $5.96), decreasing direct ownership by 2% to 313,071 units (SEC Form 4) to satisfy withholding obligation4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- PRAbeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children's Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. "Activation of CHOP is a significant step forward for the Recessive dystrophic epidermolysis bullosa (RDEB) community expanding access to ZEVASKYN in the east coast," said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. "We are excited to collaborate with Dr. Marissa
- SECSEC Form DEFA14A filed by Abeona Therapeutics Inc.DEFA14A - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- PRAbeona Therapeutics® Announces Date of First Quarter Financial ResultsCLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 305519 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be avai
- PRAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On April 30, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to eight individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 112,621 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the
- SECSEC Form DEF 14A filed by Abeona Therapeutics Inc.DEF 14A - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- SECSEC Form PRE 14A filed by Abeona Therapeutics Inc.PRE 14A - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- INSIDERSEC Form 4 filed by Goldan Keith A.4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERSEC Form 3 filed by new insider Goldan Keith A.3 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- SECAbeona Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- PRAbeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of DirectorsCLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa
- PRAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On March 31, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 8,400 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the
- PRAbeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New YorkCLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. "Activation of NewYork-Presbyterian/Columbia University Irving Medical Center as our fifth QTC significantly expands patient access to ZEVASKYN in the New York metropolitan area and across the Northeast," said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. "Partnering with an institution recognized globally for its leadership in genetic medicines a
- INSIDERSEC Form 4 filed by Seshadri Vishwas4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Abeona Therapeutics Inc.SCHEDULE 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)
- SECAbeona Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
ABEO FAQ
6 questionsWhat does Abeona Therapeutics Inc. do?
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In...Where does ABEO stock trade?
Abeona Therapeutics Inc. (ABEO) is listed on NASDAQ.What sector and industry is ABEO in?
Abeona Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ABEO?
Abeona Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $1900.00 price target on 2025-06-02.What companies are similar to ABEO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ABEO side-by-side with any of them on Quantisnow.How can I track ABEO on Quantisnow?
Quantisnow aggregates Abeona Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABEO to receive live email and push alerts on every new disclosure.